SCHEMBL476800

SCHEMBL476800

ClC1Nc2ccccc2O1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.41
ALOX5 P09917 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
BRD4 O60885 1/20 0.38
CREBBP Q92793 1/20 0.38
CYB5R3 P00387 1/20 0.37
GAA P10253 4/20 0.36
KDM4E B2RXH2 2/20 0.36
NISCH Q9Y2I1 1/20 0.34
POLB P06746 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
HPGD P15428 2/20 0.31
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8651078 0.76 GAA (0.57) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL12984932 0.73 PARP1 (0.41) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL3913009 0.73 PARP1 (0.41) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL4286553 0.73 PARP1 (0.46) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL7063218 0.73 PARP1 (0.41) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL23722589 0.73 PARP1 (0.50) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL6097831 0.73 PARP1 (0.50) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL6097826 0.73 PARP1 (0.41) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL5830221 0.73 PARP1 (0.41) PARP1ALOX5MEN1KMT2ALMNA
SCHEMBL19442758 0.73 PARP1 (0.41) PARP1ALOX5MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1071674-B1 METHOD FOR PRODUCING CHLOROBENZOXAZOLENE BAYER CROPSCIENCE GMBH (DE) 2004-08-11 EP claimed
EP-0626379-B1 Process for the preparation of 2-chlorobenzothiazole or 2-chlorobenzoxazole BAYER AG (DE) 2001-03-21 EP claimed
EP-1071674-A1 METHOD FOR PRODUCING CHLOROBENZOXAZOLENE Aventis CropScience GmbH (DE) 2001-01-31 EP claimed
WO-1999031076-A1 METHOD FOR PRODUCING CHLOROBENZOXAZOLENE AVENTIS CROPSCIENCE GMBH (DE) 1999-06-24 WO claimed
EP-0626379-A2 Process for the preparation of 2-chlorobenzothiazole or 2-chlorobenzoxazole BAYER AG (DE) 1994-11-30 EP claimed
EP-0141053-B1 METHOD FOR THE PREPARATION OF 2-CHLORBENZOXAZOLES CASSELLA Aktiengesellschaft (DE) 1987-08-19 EP claimed
EP-0087701-B1 PROCESS FOR THE PREPARATION OF 2-CHLOROBENZOXAZOLS CASSELLA Aktiengesellschaft (DE) 1986-08-20 EP claimed
EP-0141053-A1 Method for the preparation of 2-chlorbenzoxazoles CASSELLA Aktiengesellschaft (DE) 1985-05-15 EP claimed
EP-0087701-A2 Process for the preparation of 2-chlorobenzoxazols CASSELLA Aktiengesellschaft (DE) 1983-09-07 EP claimed
US-20220168279-A1 METHODS OF TREATING PAIN WITH A THIAZOLINE ANTI-HYPERALGESIC ACADIA PHARM INC (US) 2022-06-02 US disclosed
WO-2020159565-A1 METHODS OF TREATING POST-SURGICAL PAIN WITH A THIAZOLINE ANTI-HYPERALGESIC AGENT CERSCI THERAPEUTICS, INC. (US) 2020-08-06 WO disclosed
EP-3252050-A1 PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS Bristol-Myers Squibb Company (US) 2017-12-06 EP disclosed
US-20130281476-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED 2013-10-24 US disclosed
US-8497295-B2 Spiroindoline modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-30 US disclosed
EP-0141053-A1 Method for the preparation of 2-chlorbenzoxazoles CASSELLA Aktiengesellschaft (DE) 1985-05-15 EP disclosed
EP-0141053-A1 Method for the preparation of 2-chlorbenzoxazoles CASSELLA Aktiengesellschaft (DE) 1985-05-15 EP disclosed
EP-0087701-A2 Process for the preparation of 2-chlorobenzoxazols CASSELLA Aktiengesellschaft (DE) 1983-09-07 EP disclosed
EP-0087701-A2 Process for the preparation of 2-chlorobenzoxazols CASSELLA Aktiengesellschaft (DE) 1983-09-07 EP disclosed
EP-0087701-A2 Process for the preparation of 2-chlorobenzoxazols CASSELLA Aktiengesellschaft (DE) 1983-09-07 EP disclosed
EP-0066248-A1 Process for the preparation of halogeno-2-mercaptobenzoxazoles HOECHST AKTIENGESELLSCHAFT (DE) 1982-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281476-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 PARP1 4245/4885ALOX5 1105/4885MEN1 2672/4885
US-20220168279-A1 METHODS OF TREATING PAIN WITH A THIAZOLINE ANTI-HYPERALGESIC OPRK1, OPRL1, OPRD1 PARP1 3595/4885ALOX5 267/4885MEN1 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.